Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting
Merus N.V. - Common Shares (MRUS)
Last merus n.v. - common shares earnings: 8/19 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
nasdaq.com/symbol/mrus
Company Research
Source: GlobeNewswire
UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced updated interim clinical data on MCLA-145 monotherapy and in combination with pembrolizumab were presented at the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting taking place in Chicago May 31-June 4, 2024. “MCLA-145 as monotherapy or with pembrolizumab appears to have a manageable safety profile and early clinical activity in these difficult to treat cancers. Our biomarker data suggest that both dose and less frequent administration may be important determinants of clinical activity, and we are encouraged by the progress we are making with MCLA-145,” said Bill Lundberg, M.D., President, Chief Executive Officer of Merus. “As our company is now increasingly focused on our lead asset pet
Show less
Read more
Impact Snapshot
Event Time:
MRUS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRUS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRUS alerts
High impacting Merus N.V. - Common Shares news events
Weekly update
A roundup of the hottest topics
MRUS
News
- Merus (NASDAQ: MRUS) had its "buy" rating re-affirmed by analysts at Bank of America Co.. They now have a $76.00 price target on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target raised by analysts at Stifel Nicolaus from $90.00 to $99.00. They now have a "buy" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target lowered by analysts at Bank of America Co. from $80.00 to $76.00. They now have a "buy" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target raised by analysts at Canaccord Genuity Group Inc. from $54.00 to $67.00. They now have a "buy" rating on the stock.MarketBeat
- Merus (NASDAQ: MRUS) had its price target raised by analysts at BMO Capital Markets from $84.00 to $91.00. They now have an "outperform" rating on the stock.MarketBeat
MRUS
Earnings
- 5/8/24 - Beat
MRUS
Sec Filings
- 6/20/24 - Form 4
- 6/17/24 - Form 144
- 6/12/24 - Form 4
- MRUS's page on the SEC website